Clinical Pharmacology Perspective on Development of Adeno‐Associated Virus Vector‐Based Retina Gene Therapy
Open Access
- 7 March 2024
- journal article
- review article
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 115 (6) , 1212-1232
Abstract
Adeno‐associated virus (AAV) vector‐based gene therapy is an innovative modality being increasingly investigated to treat diseases by modifying or replacing defective genes or expressing therapeutic entities. With its unique anatomic and physiological characteristics, the eye constitutes a very attractive target for gene therapy. Specifically, the ocular space is easily accessible and is generally considered “immune‐privileged” with a low risk of systemic side effects following local drug administration. As retina cells have limited cellular turnover, a one‐time gene delivery has the potential to provide long‐term transgene expression. Despite the initial success with voretigene neparvovec (Luxturna), the first approved retina gene therapy, there are still challenges to be overcome for successful clinical development of these products and scientific questions to be answered. The current review paper aims to integrate published experience learned thus far for AAV‐based retina gene therapy related to preclinical to clinical translation; first‐in‐human dose selection; relevant bioanalytical assays and strategies; clinical development considerations including trial design, biodistribution and vector shedding, immunogenicity, transgene expression, and pediatric populations; opportunities for model‐informed drug development; and regulatory perspectives. The information presented herein is intended to serve as a guide to inform the clinical development strategy for retina gene therapy with a focus on clinical pharmacology.Keywords
This publication has 74 references indexed in Scilit:
- Model‐Informed Approaches and Innovative Clinical Trial Design for Adeno‐Associated Viral Vector‐Based Gene Therapy Product Development: A White PaperClinical Pharmacology & Therapeutics, 2023
- Quantitative systems pharmacology of the eye: Tools and data for ocular QSPCPT: Pharmacometrics & Systems Pharmacology, 2023
- Quantifying Antibody Persistence After a Single Dose of COVID‐19 Vaccine Ad26.COV2.S in Humans Using a Mechanistic Modeling and Simulation ApproachClinical Pharmacology & Therapeutics, 2022
- Landscape Analysis of the Application of Artificial Intelligence and Machine Learning in Regulatory Submissions for Drug Development From 2016 to 2021Clinical Pharmacology & Therapeutics, 2022
- Current and Next Steps Toward Prediction of Human Dose for Gene Therapy Using Translational Dose‐Response StudiesClinical Pharmacology & Therapeutics, 2021
- Rational Clinical Dose Selection of Adeno‐Associated Virus‐Mediated Gene Therapy Based on Allometric PrinciplesClinical Pharmacology & Therapeutics, 2021
- Insights From Survival Analyses During 12 Years of Anti–Vascular Endothelial Growth Factor Therapy for Neovascular Age-Related Macular DegenerationJAMA Ophthalmology, 2021
- Immune Response and Intraocular Inflammation in Patients With Leber Hereditary Optic Neuropathy Treated With Intravitreal Injection of Recombinant Adeno-Associated Virus 2 Carrying the ND4 GeneJAMA Ophthalmology, 2019
- Model‐Informed Drug Development: Current US Regulatory Practice and Future ConsiderationsClinical Pharmacology & Therapeutics, 2019
- Pre‐ and Postnatal Development of the Eye: A Species ComparisonBirth Defects Research, 2017